samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Roquette’s Innovative Plant-Based Solution Unlocks Possibilities for Veggie Softgel Market

ROQUETTE FRERES




GENEVA, Illinois. (November 18, 2020)

Roquette, a global leader in plant-based ingredients, pioneer of plant proteins and world-leading provider of pharmaceutical excipients, has today announced the launch of its market-first pea starch technology – LYCAGEL™ – offering a pharmaceutical grade solution for vegetarian softgel capsule formulations. The first of its kind, the formulated system delivers excellent capsule performance, while enabling manufacturers and marketers to meet rising consumer demand for plant-based products.



Comprising pea starch; carrageenan – a setting agent sourced from marine macro algae; NEOSORB® sorbitol – a plant-based ingredient suitable for nutraceutical application; and Na+ (salt) – a jellifying agent; Roquette’s LYCAGEL™ system offers a plant-based solution suitable for both nutraceutical and pharmaceutical applications that meets EU and US pharmacopeia standards.

“The launch of LYCAGEL™ marks a new era for softgel formulations and manufacturing. Manufacturers no longer need to compromise on performance when launching a vegetable softgel solution,” said Paul Smaltz, Head of Roquette’s Global Pharmaceutical business unit. “Designed to be easily adaptable to existing gelatin processes, LYCAGEL™ can support businesses in bringing vegetarian alternatives to market quickly, without significant changes to existing operations.”

Beyond processing parameters, the LYCAGEL™ system sets itself apart from other softgel approaches by offering excellent capsule strength, seal integrity, quick drying time with no stickiness, fast disintegration, and when compared to gelatin, no cross-linking and higher processing temperature suitability. In fact, LYCAGEL™ offers manufacturers greater flexibility to develop multi-ingredient and advanced formulations, as well as ingredients that require higher processing temperatures, such as pastes and waxes.

Smaltz adds: “LYCAGEL™ gives manufacturers the opportunity to take vegetarian softgel formulation further than ever before. As well as offering advanced performance, the pea starch system delivers on consumer visual appeal too – producing capsules with a transparent, shiny finish and excellent reproducibility. This launch represents Roquette’s continued commitment to ensuring its customers remain at the forefront of innovation.”

LYCAGEL™ is backed by full development support from Roquette, as an innovation partner to companies exploring this technology for their own customers. This includes materials for pilot scale; a technical data package detailing formulation, equipment and processing know-how; and remote or on-site technical scale-up support, all part of a contract research services offering to speed efficient scale-up and commercialization.
phone +33 32 163 3600
email pharma.business.unit @roquette.com
web www.roquettepharma.com
email 62080 Lestrem Cedex
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Axol Bioscience introduces multi-electrode array screening services for human iPSC-derived cells

• Expansion of Axol Bioscience’s service offering for pre-clinical drug discovery • New services combine the Company’s iPSC-derived human cells and electrophysiological expertise with Axion Biosystems’ Maestro Pro MEA platform
More info >>


White Papers

Industry Events

DIA Europe 2021

15-19 March 2021, VIRTUAL CONFERENCE

DIA Europe is the must-attend event for all life science professionals working in drug development, from discovery to marketed use. It encourages open collaboration by bringing together representatives from the entire spectrum of the life science landscape and facilitating crucial discussions across several topic tracks: Clinical Development, Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy, and many more.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement